David Broecker ’83 is busy these days, wearing two hats as: 1) CEO of BioCritica Inc., a new local firm that acquired commercialization rights to a Lilly drug to treat the blood infection sepsis, and 2) Chair of Zorion Medical located in Indianapolis.
Today’s announcement, that BioCrossroads’ Indiana Seed Fund has invested $300,000 in Zorion to develop an absorbable stent to treat cardiovascular disease, will keep him even busier. Click here to read more online in this week’s Indianapolis Business Journal.
David, a chemistry major/mathematics minor at Wabash, also earned a Master of Science from MIT and an MBA from the University of Chicago. Before returning to Indianapolis, he was president and CEO of Cambridge, Mass.-based biopharmaceutical company Alkermes Inc.
